BMS-754807

DB15399InvestigationalSmall molecule

BMS-754807 is under investigation in clinical trial NCT00908024 (Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors).

Mechanism: Pharmacologically active on Insulin-like growth factor 1 receptor and Insulin receptor
Curator reviewed
Formula / weight: C₂₃H₂₄FN₉O · 461.4948 g/mol (avg)
Code names: BMS-754807

Resolves to

Compound

UNIIW9E3353E8JCAS1001350-96-4ChEMBLCHEMBL575448ChEBI88339

Structure

InChIKeyLQVXSNNAFNGRAH-QHCPKHFHSA-NSMILESC[C@]1(CCCN1C1=NN2C=CC=C2C(NC2=NNC(=C2)C2CC2)=N1)C(=O)NC1=CN=C(F)C=C1

Targets

P08069IGF1RP06213INSRP31749AKT1

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with BMS-754807, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account